Sectors:
Min Investment:
Max Investment:
Target Investment:
(1996 - 2000)
AIARE Level 1 Certification
2018
2018
Endpoint Health is on a mission to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We built Endpoint Health from the ground up to develop and commercialize therapeutics and therapy-guiding tests, to ensure that every patient receives personalized treatment that will dramatically improve their outcomes. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time.
2018
Angel investing together with co-founders of @GeneWEAVE and @EndpointHealth
2017 - 2021
2018 - 2021
At YC, I help scientists become founders. There are now over 400 life sciences and healthcare companies funded by YC. https://www.ycombinator.com/companies?industry=Healthcare
2017 - 2018
Y Combinator has created an amazing community of founders. YC has invested in over thousands founders from 50+ countries who have started 4,000+ companies with a combined value of over $1T and that have created tens of thousands of jobs. At YC, I helped life sciences and healthcare founders build their companies. https://www.ycombinator.com/topcompanies/
2015 - 2017
2015 - 2017
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company and the world leader in in vitro diagnostics. At Roche, Diego led all research efforts related to Smarticles technology as well as the GeneWEAVE Division's intellectual property portfolio development.
2010 - 2015
2010 - 2015
GeneWEAVE was an in vitro diagnostics company that developed novel solutions to improve diagnosis and therapy choice in drug-resistant infections. Started in 2010, GeneWEAVE raised $25M in venture financing and was acquired by Roche in 2015. GeneWEAVE’s solutions were based on their proprietary Smarticles Technology, which enables users to rapidly determine the presence and phenotypic response to antibiotics of infection-causing bacteria. The technology received FDA Authorization in 2019 as a part of the Roche COBAS line of Products: COBAS vivoDx Receives FDA Clearance
2004 - 2010
2004 - 2010
The Batt Lab is led by Liberty Hyde Bailey Professor Dr. Carl A. Batt. Dr. Batt's laboratory strives to provide advancements in basic scientific research that will have a direct impact on society at large. The lab's scientists also work with the community to promote scientific understanding of students of all ages. While at the Batt Lab, I developed strategies for biofunctionalization of carbon nanotubes, quantum dots, and magnetic nanoparticles, and explored their potential as imaging agents and therapeutics. Collaborators of the lab included Ludwig Cancer Research, Memorial Sloan Kettering Cancer Center, New York Presbyterian Hospital, the Cornell NanoScale Science & Technology Facility, and the Cornell Nanobiotechnology Center. While at Cornell Diego received several fellowships including the National Institutes of Health Fellowship Ruth L. Kirschstein National Research Service Award (2007-2010), the Cornell SAGE Fellowship (2005), the Sloan Fellowship (2004), and the Cornell Nanobiotechnology Center Fellowship (2004).